OncoSil Medical Ltd (AU:OSL)
ASX:OSL
Want to see AU:OSL full AI Analyst Report?
OSL Stock Chart & Stats
AU$0.97
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.97
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$2.08
Previous CloseN/A
Volume350.23K
Average Volume (3M)24.03K
Market Cap
AU$15.66M
Enterprise ValueAU$6.77M
Total Cash (Recent Filing)AU$2.85M
Total Debt (Recent Filing)AU$42.47K
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding30,697,231
10 Day Avg. Volume8,764
30 Day Avg. Volume24,029
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.23
Price to Sales (P/S)11.20
P/FCF Ratio-1.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Core ProductOncoSil’s core device is a specialized, clinically focused targeted brachytherapy system for locally advanced pancreatic cancer. That product-centric model addresses a high unmet medical need, creating clinical adoption and regulatory barriers that can sustain competitive advantage as adoption grows.
Sustained Revenue GrowthMaterial revenue growth demonstrates growing market acceptance of the device and supports scaling benefits. If sustained, this trend helps spread fixed costs, improves unit economics, and offers a pathway to margin recovery and eventual profitability over the medium term.
Low Financial LeverageVery low debt levels reduce near-term solvency risk and give management flexibility to fund operations or strategic initiatives without heavy interest burdens. This balance-sheet stability supports longer runway and optionality for clinical or commercial investments.
Bears Say
Persistent UnprofitabilityOngoing negative margins indicate the business is not yet generating operating profits from sales and absorbs capital to sustain operations. Without structural margin improvement or scale, persistent losses will require repeated external funding and impair long-term shareholder value.
Negative Operating & Free Cash FlowNegative operating and free cash flow are a durable constraint: they shrink runway and force dependence on equity or debt raises. Even with low leverage, ongoing cash burn limits ability to invest in commercial expansion and heightens dilution or refinancing risk over months.
Very Small Internal TeamA two-person headcount signals heavy reliance on external partners or contractors for R&D, regulatory, manufacturing and commercialization. That raises execution risk for scaling the business and sustaining clinical support, making organic expansion dependent on hiring or third-party arrangements.
OncoSil Medical Ltd News
OSL FAQ
What was OncoSil Medical Ltd’s price range in the past 12 months?
OncoSil Medical Ltd lowest share price was AU$0.37 and its highest was AU$2.08 in the past 12 months.
What is OncoSil Medical Ltd’s market cap?
OncoSil Medical Ltd’s market cap is AU$15.66M.
When is OncoSil Medical Ltd’s upcoming earnings report date?
OncoSil Medical Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 96 days.
How were OncoSil Medical Ltd’s earnings last quarter?
OncoSil Medical Ltd released its earnings results on Feb 23, 2026. The company reported -AU$0.242 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.242.
Is OncoSil Medical Ltd overvalued?
According to Wall Street analysts OncoSil Medical Ltd’s price is currently Overvalued.
Does OncoSil Medical Ltd pay dividends?
OncoSil Medical Ltd does not currently pay dividends.
What is OncoSil Medical Ltd’s EPS estimate?
OncoSil Medical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoSil Medical Ltd have?
OncoSil Medical Ltd has 30,697,231 shares outstanding.
What happened to OncoSil Medical Ltd’s price movement after its last earnings report?
OncoSil Medical Ltd reported an EPS of -AU$0.242 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.538%.
Which hedge fund is a major shareholder of OncoSil Medical Ltd?
Currently, no hedge funds are holding shares in AU:OSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OncoSil Medical Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:OSL Sentiment 93%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$114.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
―
20 days / 200 days
Momentum
-67.40%
12-Months-Change
Fundamentals
Return on Equity
-372.27%
Trailing 12-Months
Asset Growth
-37.99%
Trailing 12-Months
Company Description
OncoSil Medical Ltd
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013. OncoSil Medical Limited was incorporated in 2005 and is headquartered in North Sydney, Australia.
Technical Analysis
Cyclopharm Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---